Anthrax -- United Kingdom
Porton Biopharma [PBL] has signed a modification to its existing agreement with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) worth USD 4.5 million to take its intranasal anthrax vaccine into phase 1 clinical trials.
The news follows acceptance by the FDA [US Food and Drug Administration] of the investigational new drug [IND] application submitted by the company. The trial is set to bring together Porton Biopharma's recombinant
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?6740815&promed&0
No comments:
Post a Comment